When was Reapplix founded?

Reapplix was founded in 2008 and raised its 1st funding round within a year of its incorporation.

Where is Reapplix located?

Reapplix is headquartered in Rudersdal, Denmark.

Who is the current CEO of Reapplix?

Graeme Brookes and Kira Rupprecht s of Reapplix.

Which legal entities is Reapplix associated with?

Reapplix is associated with Reapplix A/S.

How many employees does Reapplix have?

As of Aug 31, 2026, the latest employee count at Reapplix is 41.

Is Reapplix a funded company?

Reapplix is a funded company, having raised a total of $52.4M across 9 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 19, 2008.

When was the latest funding round of Reapplix?

Reapplix's latest funding was a $***** Series B round on Jul 07, 2020, with participation from 6 investors.

Where does Reapplix rank among its competitors?

Reapplix ranks 10th amongst 100 active competitors, of which 27 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Conexeu Sciences, which secured $88.5K in Aug, 2026.

Who are the top competitors of Reapplix?

Reapplix's top competitors include Trice Medical, Organogenesis and Acera Surgical. Among them, Conexeu Sciences secured the most recent funding round in August, 2026.

Reapplix - 2026 Company Profile, Team, Funding, Competitors & Financials

Reapplix is a series B company based in Rudersdal (Denmark), founded in 2008 by Bo Jesper Hansen, Rasmus Lundquist and Niels Holm. It operates as a Developer of patch system for wound healing. Reapplix has raised $52.4M in funding from investors like Seed Capital, Vaekstfonden and Novo Holdings, with a current valuation of $*****. The company has 100 active competitors, including 27 funded and 5 that have exited. Its top competitors include companies like Trice Medical, Organogenesis and Acera Surgical.

Company Details

Developer of patch system for wound healing. The company has developed a 3C Patch System that is used to separate, coagulate and pack it into a solid patch consisting of proteins, active cells, and growth factors. The solid patch is applied to the wounds where the patient's own growth factors and stem cells are used to heal the wound and diabetic foot ulcers.

Key Metrics

Founded Year

2008

Location

Rudersdal, Denmark

Stage

Series B

Total Funding

$52.4M in 9 rounds

Latest Funding Round

Series B, Jul 07, 2020, $*****

Investors

Seed Capital & 10 more

Ranked

10^th among 100 active competitors

Employee Count

41 as on Aug 31, 2026

Similar Companies

Trice Medical & 117 more

View Reapplix's full profile

Reapplix is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Reapplix A/S CIN: 31261570 , Denmark, Active	Apr 01, 2008	-	10 (As on Feb 29, 2024)

Reapplix has raised a total funding of $52.4M over 9 rounds. Its first funding round was on Feb 19, 2008. Its latest funding round was a Series B round on Jul 07, 2020 for $*****. 6 investors participated in its latest round. Reapplix has 9 institutional investors and 2 angel investors.

Here is the list of recent funding rounds of Reapplix:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 07, 2020	2671338	Series B	7741133	4973328	7977541	5749188
Sep 30, 2019	6100942	Series A	7505259	5320196	4208795	8057461
Mar 08, 2018	6098428	Series A	2367914	5261615	9833732	7774054

Access funding benchmarks and valuations. Sign up today!

View details of Reapplix's funding rounds and investors

The founders of Reapplix are Bo Jesper Hansen, Rasmus Lundquist and Niels Holm. Kira Rupprecht is the CEO of Reapplix.

Here are the details of Reapplix's key team members:

Bo Jesper Hansen: Founder of Reapplix. They are also an angel investor in 2 startups and serve on the board of 1 company.
Rasmus Lundquist: Co-Founder & Co-Owner of Reapplix. They serve on the board of 1 company.
Contact Info: 1 email address
Niels Holm: Co-Founder & COO of Reapplix. They serve on the board of 1 company.
Graeme Brookes: CEO of Reapplix.
Kira Rupprecht: CEO of Reapplix.
Contact Info: 1 email address and 1 phone number

Reapplix's Board of Directors

Reapplix's board has 3 active members. Niels Holm, Morten Have-Rasmussen and Søren Møller are part of team.

Here is the list of Reapplix's board of directors:

Name	Type	Representing	Status	Duration
Niels Holm	Team	-	Current	12y 0m
burzceh	Team	-	Past	1y 6m
typsped	Team	-	Past	9y 6m
kszirqb	Team	-	Current	9y 5m
egzkbai	Team	-	Current	7y 9m

View details of Reapplix's Founder profiles and Board Members

Reapplix's employee count trend

Reapplix has 41 employees as of Aug 26. Here is Reapplix's employee count trend over the years:

Uncover Reapplix's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Reapplix include Trice Medical, Organogenesis and Acera Surgical. Here is the list of Top 10 competitors of Reapplix, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Trice Medical 2012, King Of Prussia (United States), Series D	Minimally invasive solutions for orthopedic and podiatric procedures, improving patient outcomes	$85.5M	Health Quest Capital, Charter Capital Partners ... & 9 others	59/100
2nd	Organogenesis 1985, Canton (United States), Public	Regenerative tissue innovations for advanced wound care and surgical solutions	$30M	Spring St. Group, Eastward Capital Partners ... & 2 others	59/100
3rd	Acera Surgical 2013, St. Louis (United States), Acquired	Provider of synthetic electrospun scaffolds for regenerative medical applications	$6.32M	St. Louis Arch Angels, Missouri Technology ... & 1 others	57/100
4th	GeniPhys 2014, Zionsville (United States), Series A	Developer of collagen polymers for tissue regeneration	$13.5M	Elevate Ventures, Plug and Play Tech Center ... & 3 others	53/100
5th	BioTissue 2001, Miami (United States), Series C	Developer of regenerative biologic therapies for eye care	$110M	Ballast Point Ventures, RC Capital & 2 others	52/100
6th	Conexeu Sciences 2023, Vancouver (Canada), Public	Developer of products for skin restoration and wound care	$6.96M	-	47/100
7th	RenovoDerm 2016, Columbus (United States), Seed	Developer of nanofiber-based wound care devices	$775K	Proton Enterprises, Monte Carlo Capital & 1 others	46/100
8th	Siren 2015, San Francisco (United States), Series B	Provides smart socks for preventing diabetic foot ulcers	$43M	Mighty Capital, DCM Ventures & 22 others	45/100
9th	Polaroid Therapeutics 2022, Schlieren (Switzerland), Unfunded	Developer of antimicrobial solutions for wound healing	-	-	44/100
10th	Reapplix 2008, Rudersdal (Denmark), Series B	Developer of patch system for wound healing	$52.4M	Novo Holdings, Vaekstfonden & 9 others	44/100